Notice of Allowability	Application No.	Applicant(s)
	09/530,234	STEEVES ET AL.
	Examiner	Art Unit
	Olga N. Chernyshev	1646
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>March 30, 2005</u> .		
2. The allowed claim(s) is/are 46 and 58-61.		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 		
Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
ldentifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5 🖂 Notice of Informal P	atent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	, , , , , , , , , , , , , , , , , , , ,
	Paper No./Mail Date	e
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date		
4. Examiner's Comment Regarding Requirement for Deposit		nt of Reasons for Allowance
of Biological Material	9. ☐ Other	
OLOAN OUZDANGUIDLO		
OLGA N. CHÉRNYSHEV,PH.D. PRIMARY EXAMINER		

Application/Control Number: 09/530,234 Page 2

Art Unit: 1646

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Lisa A. Haile on May 20, 2005.

2. The application has been amended as follows:

In the Claims:

- 46. (Currently Amended) A method for promoting neuron repair or regeneration in a human subject suffering from spinal cord disruption by intrathecal administration of a therapeutically effective amount of a composition comprising:
- (a) one or more complement-fixing antibodies or <u>complement-fixing</u> fragments thereof, which specifically bind to galactocerebroside (Ga1C); and
- (b) one or more complement proteins or fragments thereof, wherein at least one of the complement proteins is a C3 protein;

wherein the combination of said antibodies and complement proteins or fragments

thereof causes activation of the complement system resulting in disruption of myelin or
demyelination, thereby promoting neuron repair or regeneration.

Art Unit: 1646

- 58. (Currently Amended) The method according to claim 46, wherein the <u>complement-fixing</u> antibodies <u>fragments</u> are an immunoreactive fragment selected from the group consisting of Fv, Fab, Fab', and F(ab')2 fragments.
- 3. Figure 1 of the instant application is presented in separate panels. 37 C.F.R. § 1.84(u) (1) states that in cases when figures present partial views of a drawing, which are intended to form one complete view, whether contained on one or several sheets, the figures must be identified by the same number followed by a capital letter. For example, the two panels of Figure 1 in the instant specification should be renumbered "Figure 1A" and "Figure 1B" rather than "Figure 1". Applicant is reminded that once the drawings are changed to meet the separate numbering requirement of 37 C.F.R. § 1.84(u) (1), the specification should be amended to change the Brief Description of the Drawings and the rest of the specification to refer to each Figure accordingly. If, for example, Figure 1 is divided into Figures 1A-1B, then the Brief Description and all the references to this figure in the specification must refer to this Figure in the same manner.
- 4. Claims 46 and 58-61 are allowed. Claims 46 and 58-61 are renumbered as 1-5, respectively.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga N. Chernyshev whose telephone number is (571) 272-0870. The examiner can normally be reached on 8:00 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony C. Caputa can be reached on (571) 272-0829. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1646

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 872-9306. If this number is out of service, please call the Group receptionist for an alternative number. Faxed draft or informal communications with the examiner should be directed to (571) 273-0870. Official papers should NOT be faxed to (571) 273-0870.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Olga N. Chernyshev, Ph.D.

Primary Examiner
Art Unit 1646